valu usd unless otherwis note
strong keep track achiev high end
guidanc reiter outperform
view june quarter result demonstr power
momentum across four segment especi outsid enabl
compani exceed tough hurdl organ revenu growth
rais forecast cc revenu growth ep increas
estim well price target
recommend buy share current level
strong intern growth overcom shortfal rel
estim ww revenu y/i organ
estim offset miss
revenu growth stronger growth
four segment repeat pattern seen
believ persist well
diabet revenu jump libr gather momentum
 ww diabet revenu increas cc
diabet account
medic devic revenu categori contribut
y/i growth segment emphas pivot role believ
freestyl libr play growth patient base continu
rise global estim
ww libr sale doubl year ago
reinforc posit feedback heard ada last month
rais forecast organ revenu growth bp
mid-point non-gaap ep guidanc organ
revenu growth impli forecast
includ rapid diagnost bp fx
benefit guidanc yield ww revenu ep
guidanc move estim
new forecast would higher exchang rate remain
level three month ago
rais estim organ revenu growth ep
estim organ revenu growth year bp higher
old estim howev increas off-set smaller fx
benefit leav revenu estim unchang
ep estim goe y/i revenu
ep estim organ revenu growth
high end guidanc
also increas estim price target base
strength wit across four segment bullish
manag commentari call forecast organ
revenu growth next year versu previous revenu ep
estim go
price target share arriv use sum-of-the-part valuat
old impli multipl estim
price prior trade day market close estimate unless otherwis note
cours double-digit ep growth
product cycl refresh medic devic
diagnost cost synergi stj alr capit
deploy acceler debt repay push
abt revenu ep growth ahead sever med-tech
peer revenu estim impli
underli growth ep
estim repres growth given
momentum across four segment perceiv
upsid estim
freestyl libr repres major sourc upsid us
launch strong start growth
continu rapid pace us libr sale exceed
believ product us
alon next year libr alreadi approach
mark annual sale europ million
insulin user ww could adopt libr
shape excit year diagnost
well alr transact ad rapid diagnost
portfolio receiv fda approv first two
instrument new alin platform laboratori
diagnost other forthcom
come month alin suit gain good traction
europ five six instrument commerci
avail instrument drive high single-
nutrit
adult pediatr market
segment high-single-digit low-double-digit revenu
growth establish pharmaceut factor
drive organ revenu growth
bloomberg capit market estim upside/downside/target
arriv price target use sum-of-the-
part analysi valu report segment individu
use respect ev/ebitda multipl blend ev/
ebitda multipl ebitda estim
billion yield target key assumpt underli
valuat cc organ revenu growth
organ growth basi point increas
oper margin year addit debt
reduct beyond contempl manag
guidanc price target impli price-to-earnings multipl
ep estim
arriv upsid scenario ev/ebitda multipl
ebitda estim billion key differ
base-cas assumpt cc organ revenu
growth basi point ebit margin
expans year due higher revenu growth
faster realiz cost synergi integr stj
alr faster debt repay
downsid scenario ebitda
billion key differ base-cas assumpt
low- mid-single-digit cc organ revenu growth
basi point ebit margin expans
year due slower revenu growth slower
realiz cost synergi
exhibit estim vs report result
exhibit contribut variou segment revenu growth geographi
geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
exhibit revenu estim report result
segment reportedforecasty/i y/i us medic suppli devic
exhibit intern revenu estim report result
segment exclud fx quarterreportedforecasty/i y/i emerg medic suppli devic
exhibit revenu model
geographi worldwiderevenu revenu growth excl growth excl revenu growth excl growth revenu growth revenu excl revenu incl medic suppli devic
sum-of-the-part valuat abt five major busi base ebitda estim
yield price target individu ev/ebitda multipl use valuat
diabet establish pharmaceut multipl along
ebitda estim busi give blend ev/ebitda estim
consolid ebitda billion target impli multipl
ep estim peer group evebitda price-to-earnings multipl large-cap med-tech
compani consensu estim price target basi
risk rate price target
face risk typic global diversifi healthcar compani impedi
price target rate includ competit currenc patent litig reimburs
clinic trial risk navig fda prolong econom slump
abbott laboratori one diversifi health care product compani
world product encompass intern brand gener drug devic diagnost
except ep fy dec
